Nail involvement is an extremely common feature of psoriasis and affects approximately 50% of patients. Despite this, it is an often overlooked feature of the disease, and treatment tends to be focused on clearing the cutaneous component of psoriasis. Clinical manifestations of nail psoriasis are pitting, discolouration, onycholysis and subungual hyperkeratosis as well as nail plate crumbling and splinter haemorrhages. Nail psoriasis is associated with discomfort in many patients and leads to significant functional impairment and psychological stress. The often distressing appearance of affected nails impacts the patient tremendously in both work and social activities. Importantly, 80% of patients with psoriatic arthritis have nail psoriasis. This review discusses the incidence of nail psoriasis and the burden on the patient and illustrates when dermatologists are strategically placed to detect the early signs of more severe disease by promptly diagnosing and managing the nail component of psoriasis.

Keywords:
Nail, Psoriasis, Burden of disease
1.
Jiaravuthisan MM, Dasseville D, Vender RB, Murphy F, Muhn CY: Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol 2007;57:1–27.
2.
Gudjonsson JE, Karason A, Runardsdottir EH, et al: Distinct clinical differences between HLA-Cw*0602 positive and negative psoriasis patients – an analysis of 1019 HLA-C- and HLA-B-typed patients. J Invest Dermatol 2006;126:740–745.
3.
Krueger JG: The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002;46:1–23.
4.
McGonagle D, Tan AL, Benjamin M: The biomechanical link between skin and joint disease in psoriasis and psoriatic arthritis: what every dermatologist needs to know. Ann Rheum Dis 2008;67:1–4.
5.
Zaias N: Psoriasis of the nail. A clinical-pathology study. Arch Dermatol 1969;99:567–579.
6.
Kaur I, Handa S, Kumar B: Natural history of psoriasis: a study from the Indian subcontinent. J Dermatol 1997;24:230–234.
7.
de Jong EMGJ, Seegers BAMPA, Gulinck MK, Boezeman JBM, van de Herkhof PCM: Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients. Dermatology 1996;193:300–303.
8.
Salomon J, Szepietowski JC, Proniewicz A: Psoriatic nails: a prospective clinical study. J Cutan Med Surg 2003;7:317–321.
9.
Samman PD: The Nails in Disease, ed 3. London, William Heinemann Medical, 1978.
10.
Van Laborde S, Scher RK: Developments in the treatment of nail psoriasis, melanonychia striata and onychomycosis. Dermatol Clin 2000;18:37–46.
11.
Lawry M: Biological therapy and nail psoriasis. Dermatol Ther 2007;20:60–67.
12.
Rigopoulos D, Korfitis C, Gregoriou S, Katsambas AD: Infliximab in dermatological treatment beyond psoriasis. Expert Opin Biol Ther 2008;8:123–133.
13.
Baran R: Retinoids and the nails. J Dermatol Treat 1990;1:151–154.
14.
Augustin M, Krüger K, Radtke MA, Schwippl I, Reich K: Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology 2008;216:366–372.
15.
Taieb C, Myon E, Voisard JJ, Marin N, Corvest M: Nail psoriasis: epidemiological study in France. Poster presented at the EADV 14th Congress. London, October 2005.
16.
Gisondi P, Tinazzi I, El-Dalati G, Gallo M, Biasi D, Barbara LM, Girolomoni G: Lower limb enthesopathy in patients with psoriasis without clinical signs of arthropathy: a hospital-based case-control study. Ann Rheum Dis 2008;67:26–30.
17.
Scarpa R, Soscia E, Peluso R, et al: Nail and distal interphalangeal joint in psoriatic arthritis. J Rheumatol 2006;33:1315–1319.
18.
Tan AL, Benjamin M, Toumi H, et al: The relationship between the extensor tendon enthesis and the nail in distal interphalangeal joint disease in psoriatic arthritis – a high-resolution MRI and histological study. Rheumatology (Oxford) 2007;46:253–256.
19.
Landells I, MacCallum C, Khraishi M: The role of the dermatologist in identification and treatment of the early stages of psoriatic arthritis. Skin Therapy Lett 2008;13:4–8.
20.
Williamson L, Dalbeth N, Dockerty JL, Gee BC, Weatherall R, Wordsworth BP: Extended report: nail disease in psoriatic arthritis – clinically important, potentially treatable and often overlooked. Rheumatology (Oxford) 2004;43:790–794.
21.
Scher RK: Psoriasis of the nail. Dermatol Clin 1985;3:387–394.
22.
De Berker DA: Management of nail psoriasis. Clin Exp Dermatol 2000;25:21–23.
23.
Farber E, Nall L: Nail psoriasis. Cutis 1992;50:174–178.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.